Իսրայել - եբրայերեն - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

Իսրայել - եբրայերեն - Ministry of Health

j-c health care ltd - estradiol as hemihydrate 1.6 mg - patches - estradiol - deficiency symptoms by absence of estrogen after the menopause or after surgical removal of the ovarians. they comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. in women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.

Իսրայել - եբրայերեն - Ministry of Health

j-c health care ltd - estradiol as hemihydrate 4.8 mg - patches - estradiol - deficiency symptoms by absence of estrogen after the menopause or after surgical removal of the ovarians. they comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis.in women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.

Իսրայել - եբրայերեն - Ministry of Health

j-c health care ltd - estradiol as hemihydrate 6.4 mg - patches - estradiol - deficiency symptoms by absence of estrogen after the menopause or after surgical removal of the ovarians. they comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. in women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.

Իսրայել - եբրայերեն - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Իսրայել - եբրայերեն - Ministry of Health

medici ltd - bcg 81 mg/vial - powder for reconstitution - bcg vaccine - for the treatment of superficial transitional cell carcinoma (tcc) of the urinary bladder, regardless of antecedent intravesical treatment superficial tcc comprises the following: carcinoma in situ (cis), papillary tumors limited to the mucosa (stage ta), papillary tumors invoiving the lamina propria but not the muscle layer of the bladder (stage t1), or any combination thereof. immucyst is indicated for treatment and prophylaxis of primary or recurrent carcinoma insitu (cis) of the urinary bladder and for prophylaxis following trans-urethral resection (tur) of primary or recurrent stage ta and/or t1 papilary tumors.

Իսրայել - եբրայերեն - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

Իսրայել - եբրայերեն - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - pembrolizumab - תרכיז להכנת תמיסה לאינפוזיה - pembrolizumab 25 mg/ml - pembrolizumab

Իսրայել - եբրայերեն - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar

Իսրայել - եբրայերեն - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - טבליות מצופות פילם - losartan potassium 50 mg - losartan - losartan - hypertension: losartan is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type-2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary deposite endpoi